US FDA

21 CFR Part 210 - cGMP Foundations

What Part 210 actually establishes, how it relates to Part 211, and where cGMP's minimum-requirements standard applies.

What this course covers

21 CFR Part 210 is short, but it is the part of FDA's drug cGMP regulations that everything else in Part 211 depends on. This course covers what Part 210 establishes, the key definitions it sets for the rest of FDA's drug manufacturing regulations, and exactly which products, processes and facilities fall within cGMP scope. It is written for people who need real regulatory literacy, not a paraphrase.

Who this course is for

New QA, QC or engineering staff who need foundational regulatory literacy
Compliance and validation staff working across multiple CFR parts
Anyone who has worked around cGMP language without formally learning its source

What you'll learn

What 21 CFR Part 210 establishes and how it sets up everything in Part 211
The key definitions FDA uses throughout its drug cGMP regulations
Which products, processes and facilities actually fall within cGMP scope
How Part 210's minimum-requirements standard is applied and interpreted by FDA
Where Part 210 sits in the broader hierarchy of FDA drug regulation, alongside the FD&C Act itself

Why it matters

Part 210 is frequently skipped in training because it looks like boilerplate. In practice, scope and definition disputes, whether a process or product actually falls under cGMP, trace directly back to this part. Understanding it properly prevents a surprising number of downstream compliance arguments.

Included in the full GMPify subscription

Completion certificate, PDF slide download, and access to the complete GMP course library from day one.

Start this course →